An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J, Gao Y, Luan X, Li K, Wang J, Dai Y, Kang M, Lu C, Zhang M, Lu CX, Kang Y, Xu C.
Xu J, et al. Among authors: gao y.
Cancer Chemother Pharmacol. 2022 May;89(5):683-695. doi: 10.1007/s00280-022-04403-9. Epub 2022 Apr 13.
Cancer Chemother Pharmacol. 2022.
PMID: 35419627
Free PMC article.